Neuronetics Company Leadership

STIM Stock  USD 1.30  0.03  2.36%   
Neuronetics' insiders are aggressively selling. The analysis of insiders' sentiment of trading Neuronetics stock suggests that most insiders are panicking at this time. Neuronetics employs about 716 people. The company is managed by 15 executives with a total tenure of roughly 1671 years, averaging almost 111.0 years of service per executive, having 47.73 employees per reported executive.
Insider Sentiment
Mostly Selling
 
Selling
 
Buying

Latest Trades

2026-02-26William Andrew MacanDisposed 3427 @ 1.35View
2026-02-12William Andrew MacanDisposed 14120 @ 1.65View
2026-02-10William Andrew MacanDisposed 3485 @ 1.55View
2025-05-12Stephen FurlongDisposed 193460 @ 4.27View
Following insider trading sentiment in Neuronetics can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Neuronetics has a market cap of 88.69 M, operating margin of -19.63%, ROE of -2.19%. Review World Market Map for broader portfolio context. This reflects a position in Neuronetics within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
New to investing in Neuronetics Stock? Start with our How to Invest in Neuronetics Stock guide for a step-by-step overview.

Neuronetics Management Team Effectiveness

The company has return on total asset (ROA) of -21.21 % which indicates that it has lost $21.21 on every $100 of assets deployed. This is much lower than what is typical in the sector. Similarly, it shows a return on stockholder's equity (ROE) of -218.99 %, which implies that the business failed to generate returns adequate to cover equity costs.
As of yesterday, Common Stock Shares Outstanding is anticipated to decline to approximately 19.4 M. In addition to that, Net Loss is anticipated to decline to approximately -35.1 M

Stock Ownership Analysis

About 20.0% of the company outstanding shares are owned by corporate insiders. The book value of Neuronetics was at this time reported as 0.4. The company recorded a loss per share of 0.83. Neuronetics had not issued any dividends in recent years.

Stock Institutional Investors

Institutional ownership matters in Neuronetics because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
Shares
Fourworld Capital Management Llc2025-09-30
568 K
Morgan Stanley - Brokerage Accounts2025-09-30
475.7 K
Renaissance Technologies Corp2025-12-31
474.9 K
Millennium Management Llc
383.7 K
Northern Trust Corp2025-09-30
276.6 K
Jane Street Group Llc2025-09-30
234.6 K
Jbf Capital, Inc.2025-12-31
233.2 K
The Goldman Sachs Group Inc2025-09-30
221.9 K
Susquehanna International Group, Llp2025-09-30
220.6 K
Vanguard Group Inc2025-12-31
2.6 M
Balyasny Asset Management Llc2025-12-31
2.6 M
A large institutional presence can look reassuring, but sophisticated ownership alone should not be mistaken for proof that a position is mispriced or low risk. Ownership data should therefore support due diligence rather than replace it.

Insider Trading Activities

Insider trading disclosures for Neuronetics offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 88.69 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
 
Macan William Andrew over a week ago
Disposition of 609 shares by Macan William Andrew of Neuronetics at 1.34 subject to Rule 16b-3
 
Keith Sullivan over two weeks ago
Disposition of 8452 shares by Keith Sullivan of Neuronetics at 1.35 subject to Rule 16b-3
 
Macan William Andrew over two weeks ago
Acquisition by Macan William Andrew of 210000 shares of Neuronetics subject to Rule 16b-3
 
Furlong Stephen over a month ago
Acquisition by Furlong Stephen of 150000 shares of Neuronetics subject to Rule 16b-3
 
Pfanstiel Steven over two months ago
Acquisition by Pfanstiel Steven of 170212 shares of Neuronetics subject to Rule 16b-3
 
Macan William Andrew over three months ago
Acquisition by Macan William Andrew of 15000 shares of Neuronetics subject to Rule 16b-3
 
Furlong Stephen over three months ago
Disposition of 5813 shares by Furlong Stephen of Neuronetics at 3. subject to Rule 16b-3
 
Madryn Asset Management, Lp over six months ago
Disposition of 192806 shares by Madryn Asset Management, Lp of Neuronetics at 3.72 subject to Rule 16b-3
 
Muir Glenn P over six months ago
Acquisition by Muir Glenn P of 30000 shares of Neuronetics subject to Rule 16b-3
 
Furlong Stephen over six months ago
Disposition of 6540 shares by Furlong Stephen of Neuronetics at 4.16 subject to Rule 16b-3
 
Furlong Stephen over six months ago
Disposition of 193460 shares by Furlong Stephen of Neuronetics at 4.27 subject to Rule 16b-3
 
Keith Sullivan over six months ago
Disposition of 25934 shares by Keith Sullivan of Neuronetics at 4.41 subject to Rule 16b-3

Outstanding Bonds

Reviewing Neuronetics bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
Over half of Neuronetics' outstanding shares are owned by institutional investors. Institutional investors such as mutual funds, pension funds, and asset managers typically build positions in companies like Neuronetics as part of their portfolio management activity, investing on behalf of clients or beneficiaries. Institutional investors hold approximately 65% of Neuronetics' outstanding shares, with insiders holding 20% and 15% in the public float.
 
Shares in Circulation  
 First Issued
2018-09-30
 Previous Quarter
66 M
 Current Value
67 M
 Average Shares Outstanding
28.1 M
 Quarterly Volatility
13.8 M
Macro event markers
 
Covid
 
Interest Hikes

Neuronetics Stock Holders Distribution

Institutional ownership analysis for Neuronetics matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.

Neuronetics Market Cap and Value

Neuronetics Workforce Comparison

Neuronetics takes the leading position in number of employees compared to key competitors. The total workforce of Health Care industry is at this time estimated at about 2,932. Neuronetics totals roughly 716 in number of employees claiming about 24% of equities under Health Care sector.

Neuronetics Profit Margins

The company has Profit Margin (PM) of -34.0 %, which implies that it is absorbing losses on its sales activity. This is much lower than what is typical in the sector. Similarly, it shows Operating Margin (OM) of -20.0 %, which indicates that it has not achieved operational breakeven on its current revenue base.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.840.83
Fairly Up
Slightly volatile

Neuronetics Insider Trading History

Insider trading disclosures for Neuronetics offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 88.69 Million. Used properly, these records are better for context than for blind buy-or-sell signals.

Neuronetics Notable Stakeholders

Stakeholders matter for Neuronetics because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
Keith SullivanCEO PresidentProfile
Stephen MSSenior CEOProfile
Andrew JDGeneral VPProfile
MBA CMAChief OfficerProfile
Lisa MetznerRosasSenior OfficerProfile
Andrew MacanGen VPProfile
Claire SearsVP MarketingProfile
Rick GrubbsSenior AccountsProfile
Cory AndersonSenior ClinicalProfile
Kara ThorntonVP DirectorProfile
Rusty PageSenior QualityProfile
William LeonardChief OfficerProfile
Geoffrey MDChief OfficerProfile
Sara GrubbsSenior OfficerProfile
Jeffrey JonesSenior OperationsProfile

Management Information & Data Sources

Neuronetics is a micro-cap company in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care. Executive review focuses on insiders, senior management, and employee signals. Management quality is typically assessed through capital allocation choices and operating follow-through. CEO is Keith Sullivan with 716 employees and 15 reported executives.

Inputs for Neuronetics come from periodic company reporting and market reference feeds and are mapped into a consistent schema for analysis. Some fields can appear with publication lag. Insider and management fields are mapped from published filings and company disclosures.

This content is curated and reviewed by:

Michael Smolkin - Member of Macroaxis Board of Directors

Workforce Efficiency and Productivity

Investors reviewing Neuronetics can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.

Neuronetics Manpower Efficiency

Return on Neuronetics Manpower

Revenue Per Employee104.6K
Revenue Per Executive5M
Net Loss Per Employee61.1K
Net Loss Per Executive2.9M
Working Capital Per Employee37.5K
Working Capital Per Executive1.8M

More Resources for Neuronetics Stock Analysis

Understanding Neuronetics typically begins with financial statements and long-term trend review. Ratio context helps frame profitability, efficiency, and growth trends for Neuronetics Stock. Outlined below are key reports that provide context for Neuronetics Stock:
Neuronetics has a market cap of 88.69 M, operating margin of -19.63%, ROE of -2.19%. Review World Market Map for broader portfolio context. This reflects a position in Neuronetics within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
New to investing in Neuronetics Stock? Start with our How to Invest in Neuronetics Stock guide for a step-by-step overview.
Analysis related to Neuronetics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
 Earnings Share
-0.83
 Revenue Per Share
2.238
 Quarterly Revenue Growth
1.013
 Return On Assets
-0.21
 Return On Equity
-2.19
Neuronetics's market price can diverge from book value, the accounting figure shown on Neuronetics's balance sheet. Neuronetics' market capitalization is 88.69 M. With a P/B ratio of 3.25, the market values Neuronetics well above its book equity. Enterprise value stands at 151.63 M. Intrinsic value reflects what Neuronetics' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Neuronetics' value from its trading price, which are computed with different methods. For Neuronetics, key inputs include a P/B ratio of 3.25, a profit margin of -34.27%, ROE of -2.19%, and revenue of 74.89 M. The quoted price is simply the exchange level where supply meets demand.